Tag: Pembrolizumab

1. Concomitant pembrolizumab plus chemoradiation therapy was associated with improved antitumor activity and safety profile in patients with previously untreated, locally advanced, stage III non-small cell lung cancer. 2. This treatment regimen represents a promising therapy in patients with previously untreated, locally advanced, stage III non-small cell lung cancer, regardless...
Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.
1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma. 2. Lenvatinib plus pembrolizumab demonstrated longer progression-free survival compared to sunitinib. Evidence Rating Level: 1 (Excellent) Study Rundown: The standard treatment of advanced renal cell carcinoma (RCC) has been antagonism of vascular endothelial growth factor...
1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma. 2. Lenvatinib plus pembrolizumab demonstrated longer progression-free survival compared to sunitinib. Evidence Rating Level: 1 (Excellent) Study Rundown: The standard treatment of advanced renal cell carcinoma (RCC) has been antagonism of vascular endothelial growth...
1. In a phase 3 trial across 23 countries, Pembrolizumab displayed a longer cancer-free period when compared to the first line therapy for metastatic microsatellite instability or mismatch-repair deficiency (MSI-H-dMMR) colorectal cancer. Evidence Rating Level: 1 (Excellent) Study Rundown: A subset of colorectal cancer tumors is mismatch-repair deficiency (dMMR) which has been known...